Clinical efficacy of apatinib in the treatment of advanced lung cancer
Gao Junfang
Kuang Xiankui
Ma Xing
Lu Junfeng
Mao Shengya
Dong Wenjie
Wang Liping
Abstract：Objective To evaluate the clinical effects and safety of apatinib in advanced lung cancer patients after failure of second-line or beyond treatment.Methods Thirty-nine patients confirmed as lung cancer at stage Ⅲ~Ⅳ who failed in second-line or beyond treatment from April of 2015 to April of 2016 were collected.All patients were given oral apatinib (425 mg/d, 28 d for 1 courses).Clinical efficacy and adverse reactions were observed.Results The median PFS of all patients was 3.5 months.Median OS was 5.1 months.CR was 0% (0/39), PR was 15.4% (6/39), SD was 51.3% (20/39), and PD was 33.3% (13/39).ORR and DCR were 15.4% and 66.7%, respectively.The main adverse reactions were hypertension (35.9%), proteinuria (25.6%), hand-foot syndrome (25.6%), diarrhea (20.5%) and bone marrow suppression (38.5%).All of these side effects were relieved after positive treatment.Conclusion Apatinib exhibits objective efficacy in advanced lung cancer patients after failure of second-line or beyond treatment with manageable toxicity.
Keywords：apatiniblung cancerclinical efficacy
Publication Date：2017-01-01
Online Publishing Date：2026-09-12(First online date of this platform, not the publication date of the document)
Pages：3( 1370-1372 )